Background: The optimal treatment for primary central nervous system lymphomas (PCNSL) has not yet been defined.
Introduction
Primary central nervous system lymphomas (PCNSL) comprise 1% of brain tumors and l%-2% of extranodal non-Hodgkin's lymphomas (NHL) [1] . In the past two decades, their incidence in immunocompetent patients has increased at a higher rate than that of other extranodal NHL [2] [3] [4] . This increment is not attributable to technological developments in diagnostic methods only, since it is significantly higher than that of other brain tumors [4] .
PCNSL are usually disseminated within the central nervous system (CNS) at diagnosis [4] . They tend to infiltrate the deep regions of the brain and subependimal tissues. Thus, meningeal seeding, through cerebrospinal fluid (CSF), occurs frequently. Multiple lesions are found in about 50% of cases. An increased frequency of high-grade PCNSL, probably due to a variation of the natural history of the disease, was reported in the past decade [4] . Their prognosis is poor and the median survival of untreated patients is 1.5-3.3 months [5] . Evaluation of therapeutic results is difficult since few prospective and no randomised trials have been published. The reported series are composed of small numbers of heterogeneously-treated patients grouped by obsolete and dissimilar histopathologic classifications [5] [6] [7] .
Patients submitted to surgical resection alone have a median survival of 3.5-5 months. Moreover, gross resection increases the risk of severe and permanent neurological sequelae and of tumor cell spill through meningeal spaces [5] [6] [7] [8] [9] [10] [11] [12] , so surgery seems to have only a diagnostic role, and stereotactic biopsy is progressively replacing other surgical procedures. For a long time, radiotherapy (RT) and corticosteroids were the standard treatment, achieving complete response in most patients. Unfortunately, relapse within a few months is the rule [13] and the five-year survival rate is 3%-4%. Nowadays, chemotherapy (CHT) is considered part of the first-line treatment [11, [14] [15] [16] [17] [18] [19] [20] [21] . However, a number of therapeutic issues remain undefined.
In this paper, the impact on survival of surgery, radiation fields and doses, CHT in conjunction, or not, with RT, main antiblastic agents, intrathecal (i.t.) drug delivery and sequence of combined treatment (CTM) have been analysed by reviewing 50 series published in English between 1980 and 1995.
Patients and methods
We analyzed 50 papers published in English between 1980 and 1995 regarding the therapeutic management of PCNSL in a total of 1408 immunocompetent patients [1, 3, 8-11, 13, 15-57] , 228 having been excluded from analysis by the authors themselves.
Treatment strategy was reported for 1180 patients, but only those whose complete therapeutic management and survival data had appeared in the respective original papers were included in the present analysis, that is, 504 were excluded due to insufficient information concerning the relation between their therapeutic management and survival. There is no reason to believe that our results were affected by the exclusion of these cases since the median survival of the excluded series was similar to that of the cases considered in the analysis. The study group consists of 676 patients.
Therapeutic strategy and age distribution for treatment groups are reported in Table 1 . Surgical resection consisted of total removal in 62 cases, subtotal resection in 158 and biopsy alone in 236 cases, while the extension was not reported in 220 cases Median age was 58, 56, 58 and 60 years, respectively.
Surgical procedure was followed by further treatment in 614 cases. External irradiation was performed in 560 patients (91%), as exclusive treatment (n = 312) or in association with CHT (n = 248). Range of whole brain (WB), tumor bed and spinal axis doses are summarised in Table 2 . Radiation data were not complete for 92 patients (16%).
CHT was administered to 302 patients (49%) ( Table 1) , and for 54 of them it was the sole treatment; the regimens for 63 patients were not reported. Altogether, more than 40 different CHT regimens were employed. The use of the main antineoplastic agents and of i.t. CHT is reported in Table 3 and the sequence of CTM is listed in Table 4 .
Survival curves were generated by the Kaplan-Meier method [58] . Impact on survival of age (^ 60 vs. > 60 years), treatment strategy (untreated patients, surgery alone, RT alone, CHT alone, CTM), WB dose (involved fields (IF) vs. WB $ 40 versus WB > 40 Gy), tumor bed dose (< 50 vs. > 50 Gy), high-dose methotrexate (HD-MTX) use (yes vs. no), i.t. CHT (yes vs. no) and treatment sequence (CHT-RT versus RT-CHT) in CTM have been evaluated in univariate analyses comparing the survival curves by the log-rank test [59] . The variables with a significant impact on survival were analysed by the Cox proportional hazard model [60] to evaluate their independent role.
Results
Six hundred seventy-six evaluable patients were analysed. The median survival for the study group as a whole was 14 months (range 1-188).
Age
Age was reported for 477 patients, with 57 years as the median (range 1-89). The median survival was 12 
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Abbreviations: T dose -tumor bed dose, WB -whole brain, SC -spinal-cord dose, m -median, r -range, Sv -survival (months), IF -involved field irradiation, RT -radiation therapy, CTM -combined treatment modality, CSI -cranio-spinal irradiation, n.r.d. -not reported data. months for 181 patients >60 years and 21 months for 296 patients ^ 60 years, with a statistically significant difference (P < 0.00001, Figure 1 ).
Surgery
Surgery as the sole treatment did not appear to have improved survival time over that of untreated patients (P = 0.25; Figure 2 ).
Patients receiving CHT and/or RT after surgery had longer survivals than those who underwent surgery alone, or who received no treatment (P < 0.00001, Figure 2 ). The median survivals for both groups are reported in Table 1 .
The impact of the extent of surgery on survival was analysed: macroscopically radical resection was compared with subtotal resection and with biopsy alone. Median survivals were 17, 15, 16 and 22 months, respectively (P = 0.66).
Radiotherapy
RT variables were evaluated in patients submitted to irradiation as sole therapy. Because the radiation dosages were not given for 52 patients, only 260 of the 312 were eligible for analysis of treatment effect. The 16 patients who received spinal cord irradiation (SCI) were omitted from the analysis of optimal WB and tumor bed dose to avoid confounding factors. Survival curves for 20 patients irradiated to IF with >40 Gy, 151 patients irradiated to WB with ^ 40 Gy and 73 patients irradiated to WB with >40 Gy were compared. Median survivals were 11,14 and 22 months, respectively ( Figure  3) , with a statistically significant difference (P = 0.02). In particular, patients receiving the highest doses survived longer than those in both of the other groups (P -0.05 and 0.03, respectively). The median age of the patients treated with IF and with WB > 40 Gy (54 and 55 years, respectively) was comparable, while those receiving WB < 40 Gy were older (median 60 years). The impact of the tumor bed dose on survival in patients receiving > 40 Gy to WB was then analysed. Thirty-nine patients (median age: 54 years) received 41-50 Gy to the tumor bed and 34 (median age: 60 years) received > 50 Gy. Their median survivals were 21 and 28 months, respectively (P = 0.02).
The addition of SCI to WB irradiation failed to improve outcome. The median survival of 224 patients irradiated to WB was 17 months as compared to 14 months for 16 patients submitted to craniospinal irradiation (P = 0.36).
Chemotherapy
The CHT regimen was reported in 239 cases. Survival was analysed as a function of the use or not of each of survival curves for patients treated with chemotherapy followed by radiotherapy (CHT-RT) and for patients treated with post-irradiation chemotherapy (RT-CHT).
the four main antiblastic agents, high-dose methotrexate (HD-MTX), cyclophosphamide, nitrosoureas and adriamycin, and of i.t. CHT. Results of univariate analyses are summarised in Table 3 . Median survival for patients receiving HD-MTX ^ 1 g/m 2 (n = 119) or not (n -120) was 37 months and 23 months, respectively (P -0.04). Patients receiving i.t. CHT (n = 90) had longer survival times (median 38 months) than patients treated with systemic CHT without i.t. drug administration (n -149, median: 24 months) (P = 0.03).
Combined treatment
Patients treated with CTM had longer survivals than those treated with either RT alone (P < 0.00001) or CHT alone (P = 0.007) (Table 1, Figure 2) .
The impact of the sequence of CTM on survival was analysed by comparing 133 patients submitted to CHT-RT and 91 patients treated with RT-CHT ( Table 4 ). The median age was superimposable. HD-MTX was delivered in 71% of patients treated with CHT-RT versus 13% in the other group; i.t. CHT was administered in 48% and 26%, respectively. Fifty-six percent of the patients in the CHT-RT group and 37% in the RT-CHT group were censored. Median survival was 32 and 22 months, respectively (P -0.05) (Figure 4 ).
Multivariate analysis
Variables with statistically significant impact on survival in the univariate analyses, i.e., age, WB dose, tumor bed dose, use of HD-MTX and i.t. CHT, were selected for multivariate analysis. Complete data were available for 402 of 614 cases submitted to CHTand/or RT. All tested factors except for tumor bed dose showed an independent prognostic value (Table 5) .
Discussion
Because of the rarity of PCNSL many issues such as prognostic factors, optimal radiation fields and doses, role of CTM, more active drugs, effectiveness of i.t. CHT, sequence of therapeutic modality and efficacy of CHT alone have not been clearly defined.
Age
Most authors reported a statistically significant better survival in younger patients [11, 13, 24, 26, 39, 43, 45, 52, 61, 62] . Only a few investigators [25, 50] failed to confirm the prognostic value of age. Jellinger et al. [63] suggested that age would not have an independent prognostic role but would influence therapeutic choice. In reviewed series, no differences in age distribution among therapeutic groups were observed (Table 1) . Thus, therapeutic choice does not seem to be influenced by age, and current results suggest that, as for other lymphomas, age is a powerful independent prognostic factor. Abbreviations. P -probability; IFRT -involved field irradiation.
Surgery
In this review, patients submitted to surgery as their only treatment had survival times similar to those of untreated patients. Furthermore, the extent of their resections showed no impact on survival. Thus, while it is an essential diagnostic procedure, surgery seems to have no therapeutic role in PCNSL. Stereotactic biopsy is a safe method for obtaining pathology samples, while craniotomy is associated with an elevated risk of irreversible neurological sequelae and of spillage of tumor cells through the subarachnoid spaces [5-11, 42, 63] .
Irradiation field
Only a few of the published papers compared the results obtained with WB irradiation to IF or to SCI. Gonzales et al. [33] , in a review of 46 cases from three different series [7, 8, 33] , found no difference in disease-free (DFS) and overall survival (OS) with different field extensions. In addition to the limited number of patients, these results are conditioned by the high median survival (42 months) of Littman's series [7] [8, 33, 43] , but most of them maintain that SCI should not be given [7, 9-11, 20, 22, 23, 26, 27, 29, 32, 49, 57, 58] . In reviewed series, SCI was employed in a small number of cases without survival benefit. Extensive RT destroys a considerable amount of hemopoietic bone marrow reserve, rendering any subsequent CHT problematical. This is particularly relevant because systemic and i.t. CHT seem to improve therapeutic outcome and adequately treat meningeal seeding. Thus, SCI is probably not indicated as first-line treatment.
Whole brain dose
Some authors [6, 56] observed that a WB dose < 30 Gy does not improve outcome in untreated patients, while others viewed a WB dose >40 Gy as unnecessary [56, 57] . However, because the number of patients included in these series is small, it is difficult to detect any difference. Cox et al. [64] reported a longer survival with doses beyond 45 Gy, while others obtained better results with 2s 50 Gy [9, 23, 26] . Most retrospective studies concluded that patients should receive at least 40 Gy to WB, and that there is a plateau in local tumor control with 45-50 Gy [1, 8, 11, 21, 22, 29, 32, 33, 42, 65] . In this analysis, the survival of patients receiving > 40 Gy to the WB was significantly longer than that obtained with <40 Gy. Despite the older age of the patients in the latter group, an independent impact of WB dose on survival was confirmed by the multivariate analysis.
Tumor bed dose
In the reviewed series, 46% of patients experienced local recurrence. Since recurrence leads to death in almost all instances, local control remains a major therapeutic problem. Pollack et al. [11] suggested that the amount of radiation to the tumor bed has no effect on survival, but about half of their patients received < 40 Gy to WB. In an RTOG prospective trial [13] , a median survival of 12.2 months was obtained in 41 patients treated with 40 Gy to WB and 60 Gy to tumor bed. Despite the high dose delivered, the complete remission rate was surprisingly low (50%). Some improvement in survival has probably been masked by poor prognosis related to age since two-thirds of the patients in this series were older than 60 years (median: 66 years). It is generally agreed that a boost to the tumor bed should be employed [1, 7, 10, 22, 42, 65, 66] . Mendenhall et al. [42] recommended a tumor dose of 60-65 Gy and Murray et al. [10] observed a significant survival improvement with ^ 50 Gy. The present analysis suggests that tumor bed dose is not an independent prognostic factor, but a tumor bed dose > 50 Gy prolongs survival when WB is adequately treated.
The impact of WB and tumor bed dose on survival has not been tested in patients submitted to CTM, since the heterogeneity of CHT regimens and sequence would constitute a confusing factor in the interpretation of the results. The possibility of reducing radiation doses in CTM should be considered in future trials.
Chemotherapy associated with radiotherapy
RT alone, even when employed with optimal fields and doses, yields poor results, and, as in other extranodal intermediate or high-grade lymphomas, is insufficient to eradicate PCNSL. Several limited experiences adding various drugs and regimens to RT showed an improved outcome in comparison with RT alone [1, 11, 15-19, 21, 43, 49, 50, 55] , but only a few prospective trials have been reported [18, 25, 27, 61, 62] . Brada et al. [25] did not observe a better survival with the MACOP-B regimen plus RT than with RT alone, but 2 of 10 patients who underwent CHT died of neurological deterioration while disease-free, and follow-up was too short (14 months) for the four survivors among the eight patients who completed the planned treatment. Glass et al. [18] reported a median survival of 33 months in 25 patients submitted to HD-MTX 3.5 g/m 2 before irradiation, suggesting an advantage in both DFS and OS in comparison to the literature data of patients treated by RT alone. De Angelis et al. [27] reported a statistically significant improvement in median DFS of 31 patients treated with CHT followed by RT (41 months) compared to the historical control group receiving RT alone (10 months) and a statistically non-significant doubling of median survival (42.5 and 21.7 months, respectively). O'Neill et al. [61] reported a median survival of 11 months for 46 patients treated with the CHOP regimen followed by WBRTand post-irradiation high-dose cytarabine, concluding that treating PCNSL with CTM did not produce a survival advantage. A similar conclusion was reached by Schultz et al. [62] , who reported a median survival of 16 months in 52 patients treated with the pre-irradiation CHOD regimen in comparison to patients treated with RT alone. As explained below, the short survival obtained in the last two series could be due to the inability of cyclophosphamide and doxorubicin to cross the blood-brain barrier (BBB) underlying PCNSL.
Even if reviews have limited value due to heterogeneity of treatment in the reported series, suggestive evidence of the superiority of a CTM compared to RT alone was reported by Fine (median survival: 29.1 months versus 16.6) [67] and Jellinger (range of survival: 17-44 months versus 10-18) [65] . In the present analysis, median survival obtained with CTM was significantly superior to that obtained with RT alone. Since the median ages of the two groups were superimposable current results do not seem to be influenced by age.
Antiblastic agents
The efficacy of CHT is influenced by the heterogeneous disruption of the BBB underlying PCNSL [19, 45, 68, 69] . Its integrity is re-established within a few weeks after response to treatment, which hampers drug penetration. Consequently, active drugs that penetrate the intact BBB must be chosen. The use of the most effective cytostatics in the treatment of systemic NHL yielded poor results in PCNSL [61, 62] . In the current analysis, anthracyclines and cyclophosphamide did not improve survival, probably due to their inability to cross the BBB. A statistically significant difference in survival in favour of patients receiving HD-MTX was observed. This group is predominantly composed of cases from single institutions treated in prospective trials. Even when age and performance status were not used as selection criteria in these trials, their prospective nature may constitute a bias, and even though current data seem to suggest that HD-MTX is the most efficacious drug, further studies are necessary to confirm its role in PCNSL management.
Chemotherapy as exclusive treatment
In a preliminary report by Boiardi et al. [20] , five patients achieving complete remission with the M-BACOD regimen have not been subsequently irradiated: two of them recurred after 5 and 12 months, while three were disease-free after 11-15 months. Sarazin et al. [49] treated five elderly patients with CHT alone: two of them were alive after 11 and 21 months and three had died within 10 months. Other series [18, 19, 24, 25, 30, 37, 41, 49, 50] reported sporadic instances of patients refusing RT or having progressive disease during CHT. The current analysis suggests longer survival in patients treated with CTM than in those receiving CHT alone. However, results are biased due to the inclusion, in the latter group, of patients unable to complete the planned treatment because they were not responsive to CHT or were treated with inadequate regimens. To date, it is difficult to assess the role of CHT as exclusive treatment, and prospective trials conducted on adequate numbers of patients with effective drugs are necessary.
Intrathecal chemotherapy
The reported incidence of meningeal seeding at diagnosis is 0%-50% [1, 5, 10, 11, 13, 14, 17, 21, 38, 65, 67] . Relapse in the spinal cord occurs in 0%-25% of cases, independently of leptomeninges treatment [8, 10, 13, 27, 50, 61, 62] . In the reviewed series, CSF from 378 of 1180 patients (32%) was examined for lymphomatous cells and malignant lymphocytes or a monoclonal population of lymphocytes were identified in 100 cases (26%). The rate of leptomeningeal seeding is probably underestimated. In fact, since 1972 Schaumburg et al. [70] have observed leptomeningeal tumor in 100% of autoptic cases. De Angelis [14] reported a suspicious or atypical CSF cytology in 31% which was other than leptomeningeal, a known disease in 38% of patients. Detection of lymphomatous cells is sometimes impossible even in the presence of extensive meningeal infiltration [38] . Immunohistochemical and molecular biology methods will probably improve the reliability of results.
Treatment of leptomeninges can be achieved by SCI, high-dose systemic CHT or by i.t. drug delivery. Studies on the pharmacokinetics of systemic HD-MTX (^3 g/m 2 ) and high-dose cytarabine show, respectively, short duration (24 hours) and unpredictable drug concentrations in the CSF [71] . By contrast, i.t. MTX administration allows a more homogeneous and prolonged concentration of drug in the subarachnoid space. In particular, when delivered by Ommaya's reservoir, MTX yields homogeneous therapeutic levels for 48 hours [72] .
In this review, patients receiving i.t. CHT obtained longer survivals than patients receiving systemic CHT without i.t. drug administration. Even though HD-MTX was delivered more frequently in the i.t. group (63 versus 42%), the multivariate analysis seems to confirm the independent role of i.t. treatment. Since i.t. CHT in combination with WB irradiation and HD-MTX seems to increase the risk of leukoencephalopathy [73] , further trials are necessary to determine whether an appropriate systemic CHT is sufficient to treat leptomeninges.
Sequence of treatment
The use of CHT-RT as the optimal sequence is supported by experimental evidence. First, the pre-irradiation CHT eludes certain radiation-induced phenomena, such as the BBB restoration, endothelial proliferation and tumor-cell resistance induction, that limit the diffusion and the efficacy of cytostatics [74] . Secondly, the administration of MTX before RT seems to reduce the incidence of leukoencephalopathy [75] .
The statistically significant longer survival of the CHT-RT group over that of the RT-CHT group observed in the current analysis must be considered with caution because of the high number of censored cases (Table 4 ) and the exclusion of patients not responsive to pre-irradiation CHT who did not complete the planned treatment. Furthermore, patients treated by CHT-RT were from prospective clinical trials and a higher percentage of them had received HD-MTX and i.t. CHT than those in the RT-CHT group. Thus, the observed difference could be biased by the selection of cases. However, when planning treatment, it should be taken into account that CHT-RT seems to be the only acceptable sequence for HD-MTX delivery. Briefly, the theoretical bases that support a superiority for initial CHT should be confirmed by clinical investigations.
